Trials / Completed
CompletedNCT07058675
Myoinositol vs. Metformin for Polycystic Ovarian Syndrome (PCOS): Impact on Metabolic Health and Fertility
Myoinositol Therapy May Adjust The Metabolic Deregulation in Infertile Polycystic Ovarian Syndrome (PCOS) Women Through Modulation of The TyG Index-BMI: A Comparative Study Versus Metformin
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 156 (actual)
- Sponsor
- Benha University · Academic / Other
- Sex
- Female
- Age
- 23 Years – 47 Years
- Healthy volunteers
- Not accepted
Summary
The study aimed to assess how a 6-month insulin sensitizer therapy impacts insulin resistance, glucose tolerance, and hormonal levels in women with PCOS. Researchers evaluated 156 PCOS patients, measuring their BMI, HOMA-IR (for insulin resistance), TyG index, TyG index-BMI, and total testosterone. Participants were divided into two groups, receiving either metformin or a myoinositol/d-chiro-inositol combination for six months, after which all parameters were re-evaluated to determine the percentage of change.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin Hydrochloride 500 MG | metformin (MET) hydrochloride 500 mg three times daily as the standard insulin sensitizer. |
| DRUG | Myoinositol | myoinositol/d-chiro-inositol combination (MYO/DCI) in 40:1 ratiotwice daily |
Timeline
- Start date
- 2024-11-25
- Primary completion
- 2025-05-30
- Completion
- 2025-06-18
- First posted
- 2025-07-10
- Last updated
- 2025-07-10
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07058675. Inclusion in this directory is not an endorsement.